These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 21037195

  • 1. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G.
    J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
    [Abstract] [Full Text] [Related]

  • 2. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group.
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [Abstract] [Full Text] [Related]

  • 3. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G.
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [Abstract] [Full Text] [Related]

  • 4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 5. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, Carreter de Granda E, Sicilia Guillén F.
    Med Clin (Barc); 2006 Oct 21; 127(15):576-9. PubMed ID: 17153267
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov 21; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, Petrioli R.
    J Am Dent Assoc; 2011 May 21; 142(5):506-13. PubMed ID: 21531932
    [Abstract] [Full Text] [Related]

  • 8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 21; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 9. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE.
    J Clin Oncol; 2013 Jul 20; 31(21):2685-91. PubMed ID: 23796998
    [Abstract] [Full Text] [Related]

  • 11. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A.
    Ann Oncol; 2009 Jan 20; 20(1):117-20. PubMed ID: 18689864
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.
    J Clin Oncol; 2009 Nov 10; 27(32):5356-62. PubMed ID: 19805682
    [Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul 10; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 14. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E.
    Ann Oncol; 2009 Jan 10; 20(1):137-45. PubMed ID: 18647964
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM, Arora S, Farag AF, Guber HA.
    Endocr Pract; 2007 Jan 10; 13(3):232-8. PubMed ID: 17599853
    [Abstract] [Full Text] [Related]

  • 16. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
    Lee CY, Suzuki JB.
    Implant Dent; 2010 Feb 10; 19(1):29-38. PubMed ID: 20147814
    [Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 Feb 10; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 18. Osteonecrosis of the jaw.
    Sari E, Bulut N, Altundag K.
    J Am Dent Assoc; 2008 Apr 10; 139(4):398; author reply 398-400. PubMed ID: 18385020
    [No Abstract] [Full Text] [Related]

  • 19. Osteonecrosis of the jaw.
    Friedlander AH.
    J Am Dent Assoc; 2011 Apr 10; 142(4):370-1; author reply 372-4. PubMed ID: 21454841
    [No Abstract] [Full Text] [Related]

  • 20. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
    Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C.
    Oral Oncol; 2008 Nov 10; 44(11):1088-9. PubMed ID: 18396443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.